|Type Public limited company|
Headquarters United Kingdom
Chief business officer David Hipkiss
|Traded as LSE: CIR|
CEO Steve Harris
Revenue 10.8 million GBP (2015)
|Key people Francesco Granata, (Chairman)
Steven Harris, (CEO)|
Stock price CIR (LON) 86.19 GBX +1.19 (+1.40%)3 Mar, 5:01 PM GMT - Disclaimer
Circassia Pharmaceuticals is a specialty biopharmaceutical company developing a range of immunotherapies. It is listed on the London Stock Exchange.
The company was founded by Steve Harris and Charles Swingland in 2006. It was the subject of an Initial Public Offering in March 2014.
The company's technology, ToleroMune, was initially developed by scientists at Imperial College London. The company is in the process of developing a treatment for cat allergies.